On June 29, 2016, in Hyderabad, Suven share price opened at 204.30 and saw a little rise of 1.52% as it announced the grant of one product patent from Europe and two from Eurasia. These patents are corresponding to the NCEs or the New Chemical Entities, as they are known in full and are for the treatment of Neurodegenrative diseases disorders. The patents, respectively, are valid through 2029, 2030 and 2031. Suven has a total of twenty-one granted patents from Europe and nineteen from Eurasia a